Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016

  • ID: 3743725
  • Report
  • 74 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • 4SC AG
  • Array BioPharma Inc.
  • BIND Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • MORE
Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016

Summary

‘Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016’, provides in depth analysis on Kinesin Spindle Protein (KSP or Eg5) targeted pipeline therapeutics.

The report provides comprehensive information on the Kinesin Spindle Protein (KSP or Eg5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Kinesin Spindle Protein (KSP or Eg5)
- The report reviews Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Kinesin Spindle Protein (KSP or Eg5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kinesin Spindle Protein (KSP or Eg5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 4SC AG
  • Array BioPharma Inc.
  • BIND Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Kinesin Spindle Protein (KSP or Eg5) Overview

Therapeutics Development

Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Stage of Development

Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Therapy Area

Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Indication

Kinesin Spindle Protein (KSP or Eg5) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Companies

Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Universities/Institutes

Kinesin Spindle Protein (KSP or Eg5) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kinesin Spindle Protein (KSP or Eg5) - Companies Involved in Therapeutics Development

4SC AG

Alnylam Pharmaceuticals, Inc.

Array BioPharma Inc.

BIND Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Merck & Co., Inc.

Novartis AG

OncoTherapy Science, Inc.

Kinesin Spindle Protein (KSP or Eg5) - Drug Profiles

4SC-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-VSP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIND-267 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BQS-481 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filanesib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8267 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCVC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTSGC-A24 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Kinesin Spindle Protein for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KSP for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRI-35566 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target KIF20A, URLC10, CDCA1 for Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kinesin Spindle Protein (KSP or Eg5) - Dormant Projects

Kinesin Spindle Protein (KSP or Eg5) - Discontinued Products

Kinesin Spindle Protein (KSP or Eg5) - Featured News & Press Releases

Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO

Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme

Jul 29, 2013: Motor Protein Revs Up Cell Division

Jun 17, 2013: Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At 2013 European Hematology Association Congress

Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi’s Research

Apr 04, 2013: Array BioPharma Presents Results From Two Ongoing ARRY-520 Clinical Trials In Multiple Myeloma At 2013 International Myeloma Workshop

Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery

Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer

Dec 11, 2012: Array BioPharma Provides Updates On Clinical Data On ARRY-520 At 2012 American Society Of Hematology Meeting

Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by 4SC AG, H1 2016

Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Pipeline by Array BioPharma Inc., H1 2016

Pipeline by BIND Therapeutics, Inc., H1 2016

Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by OncoTherapy Science, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 4SC AG
  • Array BioPharma Inc.
  • BIND Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • MORE
According to our recently published report 'Kinesin Spindle Protein (KSP or Eg5) – Pipeline Review, H1 2016'; Kinesin Spindle Protein (KSP or Eg5) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Kinesin Spindle Protein (KSP or Eg5) Kinesin spindle protein (KSP) is a member of the kinesin superfamily of microtubule-based motors. It plays an important role in mitosis. It mediates centrosome separation and bipolar spindle assembly and maintenance. Inhibition of KSP function leads to cell cycle arrest at mitosis with the formation of monoastral microtubule arrays and ultimately cell death.

The report 'Kinesin Spindle Protein (KSP or Eg5) – Pipeline Review, H1 2016' outlays comprehensive information on the Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
4SC AG
Alnylam Pharmaceuticals, Inc.
Array BioPharma Inc.
BIND Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Merck & Co., Inc.
Novartis AG
OncoTherapy Science, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll